) announced that results from the phase II STARLYTE study on
SAR3419 (coltuximab ravtansine) were presented at the 50th annual
meeting of American Society of Clinical Oncology (ASCO). ImmunoGen
has an agreement with
), as per which SAR3419 is developed by ImmunoGen and licensed to
Sanofi. SAR3419 is a CD19-targeting antibody-drug conjugate (ADC).
The STARLYTE study is evaluating the efficacy and safety of SAR3419
as a single agent for the treatment of relapsed or
relapsed/refractory CD19-positive diffuse large B-cell lymphoma
(DLBCL). Patients enrolled for the study received SAR3419 (55
mg/m2) on a weekly basis for four weeks and then every other week
till the time of disease progression or discontinuation.
Data presented at ASCO revealed that SAR3419 achieved a 43.9%
objective response rate (ORR) for the per protocol population
(patients suffering from relapsed or relapsed/refractory DLBCL).
The primary objective of the STARLYTE study is to evaluate whether
SAR3419 treatment results in an ORR of at least 20% in the patient
population. Data also suggests that SAR3419 demonstrated a
favorable safety profile.
We note that SAR3419 is also being developed for the treatment of
B-cell acute lymphoblastic leukemia. ImmunoGen has progressed well
with its pipeline in the last few quarters.
The company also has multiple pipeline related events in the coming
quarters and we expect investors focus to remain on these events.
Moreover, we are also encouraged by ImmunoGen's alliances with big
companies. Apart from Sanofi, ImmunoGen has agreements with
ImmunoGen presently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the healthcare sector include Zacks Ranked
Ariad Pharmaceuticals Inc.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
IMMUNOGEN INC (IMGN): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
ARIAD PHARMA (ARIA): Free Stock Analysis Report
To read this article on Zacks.com click here.